Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company and other criteria. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.
For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
For KemPharm, Inc.: Gordon K. ”Rusty” Johnson 321-939-3416 [email protected] Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected]
